Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson’s Disease With Motor Fluctuations (CVL-751-PD-003)
The Booth Gardner Parkinson’s Care Center is conducting a phase 3, double-blind, placebo-controlled, 27-week trial to evaluate the efficacy, safety, and tolerability of tavapadon as adjunctive therapy for Parkinson’s disease in levodopa-treated adults with motor fluctuations.
Who may be eligible to participate?
Male or female patients, age 40 to 80 years (inclusive) who have been diagnosed with Parkinson’s disease (PD) with bradykinesia and motor asymmetry. Other inclusion/exclusion criteria apply.
What does participation involve?
Each subject will participate in the trial for up to approximately 35 weeks, including:
- screening (up to four weeks)
- treatment (27 weeks)
- post-treatment safety follow up (four weeks)
Subjects who complete through Week 27 of the trial may have the opportunity to enter into an open-label extension trial.
Daniel Burdick, MD, Booth Gardner Parkinson’s Care Center